EGFR and esophageal squamous cell carcinoma: A previous study has evaluated the feasibility of icotinib in patients with advanced ESCC with EGFR overexpression.17 The response rate was higher (17.6% vs 0%, P = .34) for patients with high EGFR-expressing tumors.